FDA and the European Medicines Agency both granted orphan drug designations to ABT-414, an investigational anti-epidermal growth factor receptor antibody drug conjugate developed by AbbVie. The compound is being evaluated for safety and efficacy in patients with glioblastoma multiforme.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
